Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C)

Journal of Clinical Oncology

Volumn 30, Issue 14, 2012, Pages 1620-1627

  Dewdney, Alice ^a   Cunningham, David ^a   Tabernero, Josep ^b   Capdevila, Jaume ^b   Glimelius, Bengt ^d   Cervantes, Andres ^c   Tait, Diana ^a   Brown, Gina ^a   Wotherspoon, Andrew ^a   De Castro, David Gonzalez ^a   Chua, Yu Jo ^a   Wong, Rachel ^a   Barbachano, Yolanda ^a   Oates, Jacqueline ^a   Chau, Ian ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CAPECITABINE; CETUXIMAB; K RAS PROTEIN; OXALIPLATIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER SURGERY; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HAZARD RATIO; HUMAN; LETHARGY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; RECTUM CANCER; RECTUM RESECTION; SKIN TOXICITY; STOMATITIS; WILD TYPE; ADENOCARCINOMA; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; ANALYSIS OF VARIANCE; CANCER INVASION; CANCER STAGING; CLINICAL TRIAL; COLON RESECTION; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; FOLLOW UP; INTESTINE MUCOSA; KAPLAN MEIER METHOD; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PREOPERATIVE CARE; RECTUM TUMOR; RISK ASSESSMENT; STATISTICAL MODEL; SURVIVAL; TREATMENT OUTCOME; UNITED KINGDOM;

ADENOCARCINOMA; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY, ADJUVANT; COLECTOMY; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; INTESTINAL MUCOSA; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PREOPERATIVE CARE; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84863743780     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.6036     Document Type: Article

References (43)

1. Heald RJ, Ryall RD: Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1:1479-1482, 1986
2. Havenga K, Enker WE, Norstein J, et al: Improved survival and local control after total mesorectal excision or D3 lymphadenectomy in the treatment of primary rectal cancer: An international analysis of 1411 patients. Eur J Surg Oncol 25:368-374, 1999
3. Smith NJ, Shihab O, Arnaout A, et al: MRI for detection of extramural vascular invasion in rectal cancer. AJR Am J Roentgenol 191:1517-1522, 2008
4. Smith NJ, Barbachano Y, Norman AR, et al: Prognostic significance of magnetic resonance imaging-detected extramural vascular invasion in rectal cancer. Br J Surg 95:229-236, 2008
5. Merkel S, Mansmann U, Siassi M, et al: The prognostic inhomogeneity in pT3 rectal carcinomas. Int J Colorectal Dis 16:298-304, 2001
6. Jones GT, Harkness EF, Nahit ES, et al: Predicting the onset of knee pain: Results from a 2-year prospective study of new workers. Ann Rheum Dis 66:400-406, 2007
7. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 336:980-987, 1997
8. Sauer R, Becker H, Hohenberger W, et al: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731-1740, 2004
9. Aschele C, Friso ML, Pucciarelli S, et al: A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Ann Oncol 16:1140-1146, 2005
10. Carraro S, Roca EL, Cartelli C, et al: Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: A phase II IATTGI study. Int J Radiat Oncol Biol Phys 54:397-402, 2002
11. Gérard JP, Chapet O, Nemoz C, et al: Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: The Lyon R0-04 phase II trial. J Clin Oncol 21:1119-1124, 2003
12. Sebag-Montefiore D, Glynne-Jones R, Falk S, et al: A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: A Colorectal Clinical Oncology Group (CCOG) study. Br J Cancer 93:993-998, 2005
13. Gérard JP, Azria D, Gourgou-Bourgade S, et al: Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: Results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 28:1638-1644, 2010
14. Aschele C, Cionini L, Lonardi S, et al: Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: Pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 29:2773-2780, 2011
15. Roh M, Yothers GA, O'Connell M, et al: The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncol 29:221s, 2011 (suppl; abstr 3503)
16. Rödel C, Becker H, Fietkau R, et al: Preoperative chemoradiotherapy and postoperative chemotherapy with 5-FU and oxaliplatin versus 5-FU alone in locally advanced rectal cancer: First results of CAO/ARO/AIO-04. J Clin Oncol 29:222s, 2011 (suppl; abstr LBA3505)
17. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006
18. Chung KY, Minsky B, Schrag D, et al: Phase I trial of preoperative cetuximab with concurrent continuous infusion 5-fluorouracil and pelvic radiation in patients with local-regionally advanced rectal cancer. J Clin Oncol 24:161s, 2006 (suppl 18s; abstr 3560)
19. Machiels JP, Sempoux C, Scalliet P, et al: Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Ann Oncol 18:738-744, 2007
20. Rödel C, Arnold D, Hipp M, et al: Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys 70:1081-1086, 2008
21. Hofheinz RD, Horisberger K, Woernle C, et al: Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer. Int J Radiat Oncol Biol Phys 66:1384-1390, 2006
22. Horisberger K, Treschl A, Mai S, et al: Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: Results of a phase II MARGIT trial. Int J Radiat Oncol Biol Phys 74:1487-1493, 2009
23. Bertolini F, Chiara S, Bengala C, et al: Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: A phase II study in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 73:466-472, 2009
24. Eisterer WM, De Vries A, Oefner D, et al: Neoadjuvant chemoradiation therapy with capecitabine plus cetuximab and external beam radiotherapy in locally advanced rectal cancer (LARC). J Clin Oncol 27:195s, 2009 (suppl 15s; abstr 4109)
25. Velenik V, Ocvirk J, Oblak I, et al: A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer. Eur J Surg Oncol 36:244-250, 2010
26. Glynne-Jones R, Mawdsley S, Harrison M: Cetuximab and chemoradiation for rectal cancer-is the water getting muddy? Acta Oncol 49:278-286, 2010
27. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
28. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004
29. André T, Boni C, Mounedji-Boudiaf L, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351, 2004
30. Chua YJ, Barbachano Y, Cunningham D, et al: Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: A phase 2 trial. Lancet Oncol 11:241-248, 2010
31. Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
32. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765, 2008
33. Hochster HS, Hart LL, Ramanathan RK, et al: Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE study. J Clin Oncol 26:3523-3529, 2008
34. Quirke P, Durdey P, Dixon MF, et al: Local recurrence of rectal adenocarcinoma due to inadequate surgical resection: Histopathological study of lateral tumour spread and surgical excision. Lancet 2:996-999, 1986
35. Varella-Garcia M: Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: The EGFR fluorescence in situ hybridization assay. Diagn Pathol 1:19, 2006
36. Maughan TS, Adams RA, Smith CG, et al: Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial. Lancet 377:2103-2114, 2011
37. Tveit K, Guren T, Glimelius B, et al: Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: The NORDIC VII study (NCT00145314), by the Nordic Colorectal Cancer Biomodulation Group. J Clin Oncol 29, 2011 (suppl 4; abstr 365)
38. Maas M, Nelemans PJ, Valentini V, et al: Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: A pooled analysis of individual patient data. Lancet Oncol 11:835-844, 2010
39. Hutchins G, Southward K, Handley K, et al: Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 29:1261-1270, 2011
40. Bokemeyer C, Bondarenko I, Makhson A, et al: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663-671, 2009
41. Douillard JY, Siena S, Cassidy J, et al: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 28:4697-4705, 2010
42. Dekker JW, Peeters KC, Putter H, et al: Metastatic lymph node ratio in stage III rectal cancer; prognostic significance in addition to the 7th edition of the TNM classification. Eur J Surg Oncol 36:1180-1186, 2010
43. Fernández-Martos C, Pericay C, Aparicio J, et al: Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo Cancer de Recto 3 study. J Clin Oncol 28:859-865, 2010